Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc. (NASDAQ:AVTX), filed a Form 4 on September 18, 2026, disclosing an option exercise and sale of common stock on September 16, 2026, executed under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Sullivan exercised a stock option for 12,394 shares of common stock at an exercise price of $9.88 per share on September 16, 2026.
- Shares sold: 12,394 shares of common stock were disposed of at a weighted average price of $16.3335, with individual transaction prices ranging from $15.91 to $16.65.
- Post-transaction ownership: Following the transactions, Sullivan directly holds 39,900 shares of common stock.
- Remaining options: Sullivan retains 83,848 stock options (right to buy) with an exercise price of $9.88 and expiration date of August 13, 2034.
- 10b5-1 plan: Both transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Sullivan on May 18, 2026.
Avalo Therapeutics CFO Option Exercise and Share Sale Details
According to the Form 4 filed with the SEC, Sullivan executed two linked transactions on September 16, 2026. First, he exercised a stock option (transaction code M) covering 12,394 shares of Avalo Therapeutics common stock at a conversion price of $9.88 per share. Immediately prior to the sale, his direct beneficial ownership stood at 52,294 shares, the filing disclosed.
Sullivan then sold (transaction code S) the same 12,394 shares at a reported average price of $16.3335. The filing noted that the sale was executed across multiple transactions at prices ranging from $15.91 to $16.65, and that full per-price details are available upon request to the issuer, any security holder, or SEC staff. After the sale, his direct holdings in common stock totaled 39,900 shares, according to the filing.
In Table II, the filing reports that Sullivan retains 83,848 stock options with an exercise price of $9.88, expiring August 13, 2034. The filing indicates the option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to continued service on each vesting date. The filing states both the exercise and the sale were made pursuant to a Rule 10b5-1 trading plan that Sullivan adopted on May 18, 2026. The form was signed by Christopher Sullivan and dated September 18, 2026.
What Was Disclosed
The filing reports that Avalo Therapeutics CFO Christopher Ryan Sullivan exercised 12,394 stock options at $9.88 per share and sold the resulting shares at an average of $16.3335, all under a pre-established 10b5-1 plan, leaving him with 39,900 shares held directly.



Please wait processing your request...